Sputnik Light vaccination of volunteers began in Moscow

MOSCOW, February 27 – RIA Novosti. The first participants in the Sputnik Light coronavirus vaccine study were vaccinated in Moscow, Anastasia Rakova, Deputy Mayor for Social Development, told reporters.

“As the volunteers are examined, the volume of vaccinations will increase. Now applications are actively being submitted, in two days 490 people underwent medical examination,” she said.

The Vice Mayor recalled that anyone over 18 years of age can become a volunteer, as long as they have not been sick or sick with COVID-19 (and have not had ARVI in the last two weeks), have not been vaccinated for a month (including against coronavirus ), it does not have antibodies to SARS-CoV-2 and severe allergic reactions or exacerbation of allergies. It is not recommended for people suffering from severe chronic diseases to participate in the study, and pregnant or lactating women cannot volunteer.

“It is assumed that this vaccine will be used for young people from 18 to 30 years old, who develop a good immune response and already at the first replication they develop sufficient antibodies. Sputnik Lite in combination with Sputnik V will give more opportunities for vaccination “, – said Rakova. The spread of coronavirus

She added that the study uses all the digital developments that have already proven themselves during the tests of “Sputnik V” – electronic examination protocols, a mobile application “Volunteer Diary” and a telemedicine center.

In addition, they plan to conduct a study of the nasal form of the coronavirus vaccine in Moscow, Rakova said. The Gamaleya Center is preparing a package of documents to obtain permission from the Ministry of Health. It is assumed that the nasal form of the vaccine is suitable for those who are contraindicated in injections.

Another study that is planned in the capital is the test of “Sputnik V” for teenagers, the vice mayor continued.

“Trials of the Sputnik V vaccine for adolescents can begin only after receiving a permanent registration certificate for Sputnik V for adults, when the results of clinical post-marketing trials are finally summed up. We very much hope that this issue will be resolved within a few months,” she said Rakov, noting that the developers prepare documents, work out the technology and features of the sample. Moscow proposed the Z. A. Bashlyaeva City Children's Hospital as one of the clinical bases for this study.

In the capital, research is also ongoing on the stability of immunity after vaccination, which will determine when it will be necessary to vaccinate again. “We select two thousand volunteers and within six months we will take blood from them for antibodies every month. I really hope that by the end of summer – beginning of autumn, we will have already formed the necessary data package, which will allow us to draw more reasonable conclusions about the duration of immunity,” – concluded the vice-mayor.

The Sputnik V vaccine was developed by the Gamaleya National Research Center for Epidemiology and Microbiology with the support of the Russian Direct Investment Fund . It is based on the well-studied human adenoviral vector platform and is designed to be administered in two doses three weeks apart. According to the results of the third phase of clinical trials, Sputnik V showed an efficiency of 91.6 percent, it provides one hundred percent protection against severe cases.

Sputnik Lite is the first component of Sputnik V. According to the head of the Gamaleya Center Alexander Gintsburg , such a vaccination will give protection for four to five months and will reduce the likelihood of a severe course of COVID-19.

In Moscow, vaccination against coronavirus for risk groups began in December, and mass vaccinations throughout Russia started in mid-January. It was reported that about four million Russians have already been vaccinated.

In addition to “Sputnik V”, two more vaccines are registered in Russia – “EpiVacCorona” from the Novosibirsk center “Vector” and “Kovivak”, created by the Chumakov Federal Research and Development Center for Immunobiological Preparations.

Author: wedocount

Leave a Reply

Your email address will not be published. Required fields are marked *